# OnCo record nct05970497 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05970497/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05970497", "NCT05970497" ;
  schema:name "A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Relatlimab + nivolumab, Pembrolizumab in melanoma, run by Krystal Biotech, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05970497/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05970497> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-10-31" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/krystal-biotech/> .